The US Food and Drug Administration (FDA) has accepted Merck’s Prevymis (letermovir) for prophylaxis of cytomegalovirus (CMV) disease in kidney transplant patients for priority review.
The group has introduced a downloadable guide, interactive quiz, and other tools to inform patients from underrepresented communities about trial participation.
The Stoneygate and Kidney Research UK Alport Research Hub aims to accelerate research and develop treatments for Alport syndrome, a rare genetic disorder.
The drug discovery company reportedly used AI-powered drug discovery to come up with a promising preclinical candidate for treatment of the kidney ailment.
